Join
Live feed
·
PRReleasevia Quantisnow
Silverback Therapeutics Inc. logo

Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
SBTX· Silverback Therapeutics Inc.
Consumer Discretionary

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SBTX (Silverback Therapeutics Inc.) and more on Quantisnow.